“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
Early glucocorticoid tapering in juvenile systemic lupus erythematosus is feasible without added flare risk, though anti-double-stranded DNA positivity signals higher relapse odds.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Testimony from former CDC leadership highlighted differences with federal health officials on the process for reviewing and implementing vaccine policies.
Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.